Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A **tetravalent conjugate vaccine** for the prevention of invasive disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. It consists of capsular polysaccharides from each serogroup covalently linked to diphtheria toxoid as a protein carrier. This conjugation induces a T-cell dependent immune response and immunological memory, improving protection especially in infants and young children compared to plain polysaccharide vaccines. The vaccine is used for active immunization of individuals (typically from 9 months to 55 years old) at risk for meningococcal disease, particularly in settings of outbreaks, or for population-based prevention. It does not provide protection against serogroup B meningococcal disease[1][2][3].
- Brand names
- Menactra
- Other names
- meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccineMenACWY-Dtetravalent meningococcal A, C, Y and W-135 conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)TLR2 (Toll-like Receptor 2)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on meningococcal group A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine.